Chong Kun Dang Pharmaceutical Corp.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1941-01-01

Employees: 2.3K

Market Cap: -

Website: http://www.ckdpharm.com

Clinical Trials

CKD-397 Drug-drug Interaction Study (A)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Cialis Tab. 5mg
Drug: Harnal-D Cap. 0.2mg

First Posted Date: 2014-09-25

Last Posted Date: 2015-08-20

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 16

Registration Number: NCT02247518

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju-si, Korea, Republic of

The Efficacy of a Combination of Telmisartan/S-Amlodipine Compared With Telmisartan Monotherapy

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Telmitrend®Tab. 80mg
Drug: Telminuvo®Tab. 40/2.5mg

First Posted Date: 2014-09-04

Last Posted Date: 2020-01-31

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 217

Registration Number: NCT02231788

Locations: 🇰🇷
Bundang Cha Hospital, Seongnam, Bundang-gu, Korea, Republic of
🇰🇷
Seoul University Hospital, Seoul, Jongro-gu, Korea, Republic of
🇰🇷
Kumi cha Hospital, Gumi, Gyeongsangbuk-do, Korea, Republic of

and more 8 locations

A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension

Phase 2

Conditions: Essential Hypertension

Interventions: Drug: Candesartan 8mg
Drug: Candesartan 16mg
Drug: Amlodipine 10mg
Drug: Amlodipine 5mg

First Posted Date: 2014-08-01

Last Posted Date: 2015-03-30

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 456

Registration Number: NCT02206165

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Korea, Republic of

Bioequivalence Study (Candesartan 8 mg and Amlodipine 5 mg)

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Candesartan 8mg and Amlodipine 5mg
Drug: CKD-330 8/5mg

First Posted Date: 2014-07-10

Last Posted Date: 2014-12-02

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 32

Registration Number: NCT02186496

Locations: 🇰🇷
Chungnam National University Hospital, Daejeon, Chungcheongbuk-do, Korea, Republic of

Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519

Phase 1

Completed

Conditions: Dyslipidemia

Interventions: Drug: CKD-519
Drug: placebo

First Posted Date: 2014-06-05

Last Posted Date: 2015-09-11

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 41

Registration Number: NCT02156544

Locations: 🇰🇷
Severance Hospital, Seoul, Seodaemun-gu, Korea, Republic of

CKD-337 Drug Interaction Study

Phase 1

Completed

Conditions: Dyslipidemia (Fredrickson Type Ⅱb)
Dyslipidemia (Fredrickson Type Ⅱa)

Interventions: Drug: Fenofibrate
Drug: Atorvastatin

First Posted Date: 2014-02-19

Last Posted Date: 2017-08-08

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 30

Registration Number: NCT02066207

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

CKD-330 Drug-Drug Interaction Study (Candesartan)

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Candesartan 32mg
Drug: Candesartan 32mg/Amlodipine 10mg

First Posted Date: 2014-02-17

Last Posted Date: 2014-09-03

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 24

Registration Number: NCT02064621

Locations: 🇰🇷
Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of

CKD-330 Drug-Drug Interaction Study (Amlodipine)

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Amlodipine 10mg/Candesartan 32mg
Drug: Amlodipine 10mg

First Posted Date: 2014-02-17

Last Posted Date: 2014-08-15

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 24

Registration Number: NCT02064556

Locations: 🇰🇷
Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of

CKD-346 DDI Study(Telmisartan/S-Amlodipine, Rosuvastatin)

Phase 1

Completed

Conditions: Hyperlipidemia
Hypertension

Interventions: Drug: Telmisartan/S-Amlodipine
Drug: Rosuvastatin
Drug: Telmisartan/S-Amlodipine + Rosuvastatin

First Posted Date: 2014-01-28

Last Posted Date: 2014-04-17

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 64

Registration Number: NCT02047175

Locations: 🇰🇷
The catholic university of Korea, seoul ST.Mary's hospital, Seoul, Gangnam-gu, Korea, Republic of

Comparative Evaluation of Pharmacokinetics After CKD-501 Between Renal Impaired and Normal Renal Function Subjects

Phase 1

Completed

Conditions: Healthy
Renal Impairment

Interventions: Drug: CKD-501

First Posted Date: 2013-12-11

Last Posted Date: 2016-12-06

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 28

Registration Number: NCT02007941

Locations: 🇰🇷
The Inje University Busan Paik Hospital, Busan, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy